Courses

CAR T Research and Treatment Advances in Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Follicular Cell Lymphoma (FL) Therapies
Oncology

CAR T Research and Treatment Advances in Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Follicular Cell Lymphoma (FL) Therapies

This CME program will highlight recent advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and follicular cell lymphoma (FL). The expert faculty, led by Jeremy S. Abramson, MD, will first provide an update on CAR T cell therapies in 2024, including a summary of current approvals in the lymphoma treatment landscape ...
View Course
The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Oncology

The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This CME program, derived from content presented at the AACR Annual Meeting 2023 in Orlando, FL, will highlight the advancing role of PARP inhibitor combination therapies to improve outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC). The expert faculty, led by Dr. Alan Tan, will first review the science, mechanism of action, and clinical rationale for PARP-inhibitors and PARP-inhibitor/androgen ...
View Course

Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC
Oncology

Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC

This CME program, derived from content presented at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland, will highlight the utilization of immunohistochemistry testing, biomarkers, and targeted therapeutics to optimize outcomes in patients with non-small cell lung cancer (NSCLC). The expert faculty, led by Dr. Solange Peters, will first review the scientific advances for the identification of NSCLC biomarkers, and associated ...
View Course

Applying Poly (ADP-ribose) Polymerase (PARP) Inhibitors to Maintenance Treatment Plans to Improve Outcomes for Patients with Advanced Ovarian Cancer
Oncology

Applying Poly (ADP-ribose) Polymerase (PARP) Inhibitors to Maintenance Treatment Plans to Improve Outcomes for Patients with Advanced Ovarian Cancer

This CME/CE program will highlight the application of poly (ADP-ribose) polymerase (PARP) inhibitors to improve outcomes for patients with advanced ovarian cancer. The expert faculty, led by Dr. Don Dizon, will first review updates to the National Comprehensive Care Network (NCCN) evidence-based guidelines. Next, an analysis of current and emerging clinical trial data of PARP Inhibitors will be discussed. Following, ...
View Course

Advances in Biomarkers and Anti BCMA Therapeutics to Improve Outcomes in Patients with Relapsed/Refractory Multiple Myeloma
Oncology

Advances in Biomarkers and Anti BCMA Therapeutics to Improve Outcomes in Patients with Relapsed/Refractory Multiple Myeloma

This CME/CE program will highlight recent advances in the treatment and management of patients with relapsed/refractory multiple myeloma (RRMM). The expert faculty, led by C. Ola Landgren, MD, will first discuss best practices for integrating BCMA-targeted therapy into treatment plans for patients with RRMM. Following, emerging therapies in relapsed and remitting multiple myeloma will be reviewed, analyzing both current options ...
View Course
Therapeutic Advances in the Management of Patients with Gastrointestinal Cancer
Gastroenterology, Oncology

Therapeutic Advances in the Management of Patients with Gastrointestinal Cancer

This CME post-conference review and analysis will highlight therapeutic advances in the management of patients with gastrointestinal cancer, including data presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2022. The expert faculty will analyze the latest therapeutic advances for the treatment and management of gastrointestinal (GI) cancer as presented at ASCO GI 2022. They will also ...
View Course
Advances in the Management of Patients with Metastatic Breast Cancer
Oncology

Advances in the Management of Patients with Metastatic Breast Cancer

This CME/CE program will outline recent advances in the treatment and management of patients with metastatic breast cancer. The expert faculty, led by Dr. Harold J. Burstein, will first cover ER-positive breast cancer, analyzing data for CDK 4/6 inhibitors, ER targeting agents and antibody drug conjugates. Following, pertinent information regarding triple negative breast cancer will be reviewed, highlighting clinical implication ...
View Course
Oncology

New Challenges for the Advanced Practitioner for Optimal Patient Education

In this module, Jamie Faber, PA-C, along with Scott Kopetz, MD, PhD, course chair, will first delve into the practical considerations of biomarker testing for the interprofessional team. The expert faculty will also provide an overview of ctDNA, including the clinical implications in the colorectal cancer landscape. Following, best practices for managing adverse events to improve patient outcomes will be ...
View Course
Post Conference Review and Analysis of mCRC Data from ESMO GI 2021
Oncology

Post Conference Review and Analysis of mCRC Data from ESMO GI 2021

In this module, Michael Sangmin Lee, MD, along with Scott Kopetz, MD, PhD, course chair, will review data presented at the ESMO World Congress on Gastrointestinal Cancer 2021 Meeting. The faculty will outline a few key studies from the meeting, focusing on populations such as those who were previously untreated and patients who received prior bevacizumab treatment. Current topics such ...
View Course
Post Conference Review and Analysis of mCRC Data from ASCO 2021
Oncology

Post Conference Review and Analysis of mCRC Data from ASCO 2021

In this module, Michael Overman, MD, along with Scott Kopetz, MD, PhD, course chair, will highlight information presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The faculty will first analyze data regarding frontline metastatic colorectal cancer (mCRC), including the Keynote 177 and FOCUS 4N studies. Following, updates for both second-line mCRC and refractory mCRC therapeutics will ...
View Course